A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Investigate the Glucose Lowering Effect, Safety and Tolerability of 24 Weeks Treatment With Vildagliptin 100 mg o.d. Versus Placebo Followed by a 12 Weeks Treatment Period With Open-Label Vildagliptin 100 mg o.d. as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin.

Trial Profile

A Multicenter, Randomized, Double-Blind, Parallel-Group Study to Investigate the Glucose Lowering Effect, Safety and Tolerability of 24 Weeks Treatment With Vildagliptin 100 mg o.d. Versus Placebo Followed by a 12 Weeks Treatment Period With Open-Label Vildagliptin 100 mg o.d. as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin.

Completed
Phase of Trial: Phase III

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Vildagliptin (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novartis
  • Most Recent Events

    • 31 Jul 2012 Planned number of patients (400) added as reported by European Clinical Trials Database.
    • 02 Oct 2009 Results presented at the 45th Annual Meeting of the European Association for the Study of Diabetes (EASD).
    • 21 Jul 2009 Actual end date (July 2008) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top